Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Trial of LY2409021 in Type 2 Diabetes Mellitus
2010-023231-42Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of adomeglivant in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change from baseline in HbA1c and Safety and tolerability. Started Dec 2010; status: completed.
02
Drugs
adomeglivant
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-023231-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023231-42.